Interview with Amy E. Cyr, MD, FACS: Personalization of Management for High-Risk Women

Interview with Amy E. Cyr, MD, FACS: Identification and Management for High-Risk Women

Interview with Ashley Frith, MD: Metastatic Disease Research Highlights from the 2025 San Antonio Breast Cancer Symposium

View all

Welcome to the HR+ HER2– Breast Cancer Resource Center! We are pleased to offer a curated selection of current information, practice advancements, literature highlights, and professional resources focused on this clinical area. Our goal is to support advanced practitioners in their critical role of providing evidence-based, high-quality care to patients.

For any questions, comments, suggestions or to request information on a specific topic, please contact us at jadpro-editor@conexiant.com.

Katie Newlin, Katie Newlin, RN, MSN, AGPCNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

Lisa Salem, MSN, FNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

Evidence-Based Approaches for the Management of Side-Effects of Adjuvant Endocrine Therapy in Patients with Breast Cancer

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study

Clinical Characteristics and Treatment Persistence in US Patients with HR+/HER2-, Node Positive Early Breast Cancer Treated with Abemaciclib: Real-World Study from First Year After Approval

Vaginal Estrogen Therapy Use and Survival in Females with Breast Cancer

Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update

Breast Cancer Research and Treatment

Prognosis and endocrine therapy efficacy in early breast cancer with estrogen receptor low expression

The Breast

How should we manage abemaciclib in the peri-operative period during secondary breast reconstruction: Balancing oncologic benefit and surgical safety

Anti-Cancer Drugs

Efficacy and safety of fulvestrant combined with abemaciclib in patients with hormone receptor-positive advanced breast cancer

Anti-Cancer Research

Radiological complete response as a prognostic marker in HR-positive metastatic breast cancer treated with CDK4/6 inhibitors: Implications for treatment de-escalation

JAMA

Risk-based vs annual breast cancer screening: The WISDOM randomized clinical trial

Cancer Treatment Reviews

Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review

The American Surgeon

Assessing nodal positivity in men 70 years of age and older with clinically node negative hormone-receptor positive breast cancer to guide axillary intervention

The Breast

Genomic landscape of metastatic breast cancers in young adults: A liquid biopsy analysis of women aged 20-40 years

ESMO Open

A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: The RibOB study

HR+ HER2- Breast Cancer Resource Center

Interview with Amy E. Cyr, MD, FACS: Personalization of Management for High-Risk Women

Evidence-Based Approaches for the Management of Side-Effects of Adjuvant Endocrine Therapy in Patients with Breast Cancer

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study

Clinical Characteristics and Treatment Persistence in US Patients with HR+/HER2-, Node Positive Early Breast Cancer Treated with Abemaciclib: Real-World Study from First Year After Approval

Vaginal Estrogen Therapy Use and Survival in Females with Breast Cancer

Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update

Breast Cancer Research and Treatment

Prognosis and endocrine therapy efficacy in early breast cancer with estrogen receptor low expression

The Breast

How should we manage abemaciclib in the peri-operative period during secondary breast reconstruction: Balancing oncologic benefit and surgical safety

Anti-Cancer Drugs

Efficacy and safety of fulvestrant combined with abemaciclib in patients with hormone receptor-positive advanced breast cancer

Anti-Cancer Research

Radiological complete response as a prognostic marker in HR-positive metastatic breast cancer treated with CDK4/6 inhibitors: Implications for treatment de-escalation

JAMA

Risk-based vs annual breast cancer screening: The WISDOM randomized clinical trial

Cancer Treatment Reviews

Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review

The American Surgeon

Assessing nodal positivity in men 70 years of age and older with clinically node negative hormone-receptor positive breast cancer to guide axillary intervention

The Breast

Genomic landscape of metastatic breast cancers in young adults: A liquid biopsy analysis of women aged 20-40 years

ESMO Open

A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: The RibOB study

Clinical Cancer Research

Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer open access

Navigating Treatment Adherence in Early-Stage Breast Cancer

Isolated Brain Metastasis in BRCA2-Mutated HR+ HER2- Breast Cancer

Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer